A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
; (6): 578-582, 2023.
Article
en En
| WPRIM
| ID: wpr-1009919
Biblioteca responsable:
WPRO
ABSTRACT
A 68-year-old male was admitted due to fatigue and poor appetite and diagnosed pathologically as pancreatic adenocarcinoma with liver metastasis. The tumor marker carbohydrate antigen 199 (CA199) level was 2003.4 U/mL. The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (penpulimab). However, the tumor did not shrink and CA199 level was even higher. Anlotinib was added from the 3rd cycle, and the size of primary tumor and metastatic lesions were significantly reduced. Laparoscopic distal pancreatectomy and splenectomy as well as liver metastasis resection was performed. Three cycles of combined therapy were adopted after surgery followed by maintenance therapy with anlotinib plus penpulimab. There was no evidence of tumor recurrence during the follow-up (nearly 19 months since diagnosis).
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Pancreatectomía
/
Neoplasias Pancreáticas
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Inmunoterapia
/
Neoplasias Hepáticas
/
Recurrencia Local de Neoplasia
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Journal of Zhejiang University. Medical sciences
Año:
2023
Tipo del documento:
Article